Taho Pharmaceuticals’s apixaban-based oral dissolving strips were discovered to be a bioequivalent of Pfizer and Bristol-Myers Squibb’s (BMS) Eliquis in a Phase II trial. The randomised open ...
Patients were randomized in a double-blind fashion to receive 2.5 mg or 5 mg apixaban (Eliquis; Bristol Myers Squibb) twice daily for 12 months. The median time between the index VTE and enrollment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback